A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
NCT ID: NCT00236067
Last Updated: 2014-05-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
440 participants
INTERVENTIONAL
2004-10-31
2006-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
NCT00236015
A 10-Week Efficacy and Safety Study for of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
NCT00236054
Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults With Generalized Anxiety Disorder.
NCT00214994
Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder
NCT00233675
Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder
NCT00208741
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gabitril
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Have been diagnosed with any other psychiatric Axis I disorder (except GAD) as a principal diagnosis within the past six months
* Have been diagnosed with any eating disorder within the past six months
* Have any history of OCD, psychotic disorder, bipolar disorder or antisocial personality disorder
* Have any history of alcohol or substance abuse within 3 months of screening
* Have any history of seizures, including febrile seizures
* Have any history of head trauma associated with loss of consciousness within the past 15 years
18 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cephalon
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham Research Group
Birmingham, Alabama, United States
Southwestern Research Institute
Beverly Hills, California, United States
Pharmacology Research Institute
Northridge, California, United States
Pacific Clinical Research
Orange, California, United States
Carman Research
Smyrna, Georgia, United States
Hawaii Clinical Research Center
Honolulu, Hawaii, United States
Hartford Research Group
Florence, Kentucky, United States
Summit Research Network
Okemos, Michigan, United States
CNS Research Institute
Clementon, New Jersey, United States
Social Psychiatry Research Inst.
Brooklyn, New York, United States
Neurobehavioral Research, Inc.
Lawrence, New York, United States
Social Psychiatry Research Inst.
New York, New York, United States
The Medical Research Network
New York, New York, United States
Northcoast Clinical Trials
Beachwood, Ohio, United States
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Summit Research Network
Portland, Oregon, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Carolina Clinical Research Services
Columbia, South Carolina, United States
Radiant Research, Salt Lake City
Salt Lake City, Utah, United States
Comprehensive Neuroscience of Northern Virginia
Arlington, Virginia, United States
Summit Research Network
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C6671/3031/AX/US
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.